Editas Medicine, a genome editing company, has named James Mullen as its new chairman of the board of directors, it was reported yesterday.
Mullen has more than 30 years' experience leading biotechnology and pharmaceutical organisations on a global scale. Earlier, he has served as chief executive officer of Patheon. Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
Katrine Bosley, president and chief executive officer of Editas Medicine, said, 'Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board. Jim's extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business